首页> 外文期刊>Journal of the American Chemical Society >Ordering of the N-Terminus of Human MDM2 by Small Molecule Inhibitors
【24h】

Ordering of the N-Terminus of Human MDM2 by Small Molecule Inhibitors

机译:小分子抑制剂对人类MDM2 N末端的排序

获取原文
获取原文并翻译 | 示例
       

摘要

Restoration of p53 function through the disruption of the MDM2-p53 protein complex is a promising strategy for the treatment of various types of cancer. Here, we present kinetic, thermodynamic, and structural rationale for the remarkable potency of a new class of MDM2 inhibitors, the piperidinones.While these compounds bind to the same site as previously reported for small molecule inhibitors, such as the Nutlins, data presented here demonstrate that the piperidinones also engage the N-terminal region (residues 10-16) of human MDM2, in particular, Vall4 and Thrl6. This portion of MDM2 is unstructured in both the apo form of the protein and in MDM2 complexes with p53 or Nutlin, but adopts a novel β-strand structure when complexed with the piperidinones. The ordering of the N-terminus upon binding of the piperidinones extends the current model of MDM2-p53 interaction and provides a new route to rational design of superior inhibitors.
机译:通过破坏MDM2-p53蛋白复合物来恢复p53功能是治疗各种类型癌症的一种有前途的策略。在这里,我们介绍了新型MDM2抑制剂哌啶子酮的强大功效的动力学,热力学和结构原理,尽管这些化合物与小分子抑制剂(如Nutlins)先前报道的相同位点结合,但此处提供的数据证明哌啶子酮也参与人MDM2的N-末端区域(残基10-16),特别是Vall4和Thr16。 MDM2的这一部分在蛋白质的载脂蛋白形式和与p53或Nutlin形成的MDM2复合物中均未结构化,但在与哌啶子酮复合时采用新的β链结构。 N-末端在哌啶子酮结合后的顺序扩展了MDM2-p53相互作用的当前模型,并为合理设计高级抑制剂提供了一条新途径。

著录项

  • 来源
    《Journal of the American Chemical Society》 |2012年第41期|p.17059-17067|共9页
  • 作者单位

    Molecular Structure & Characterization, Amgen, Inc., Thousand Oaks, California 91320, United States;

    Molecular Structure & Characterization, Amgen, Inc., Thousand Oaks, California 91320, United States;

    Protein Technology, Amgen. Inc., Thousand Oaks, California 91320, United States;

    Molecular Structure & Characterization, Amgen, Inc., Cambridge, Massachusetts 02139, United States;

    Protein Technology, Amgen. Inc., Thousand Oaks, California 91320, United States;

    Department of Medicinal Chemistry, Amgen, Inc., South San Francisco, California 94080, United States;

    Molecular Structure & Characterization, Amgen, Inc., South San Francisco, California 94080, United States;

    Protein Technology, Amgen, Inc., Cambridge, Massachusetts 02139, United States;

    Molecular Structure & Characterization, Amgen, Inc., Thousand Oaks, California 91320, United States;

    Molecular Structure & Characterization, Amgen, Inc., Cambridge, Massachusetts 02139, United States;

    Molecular Structure & Characterization, Amgen, Inc., Thousand Oaks, California 91320, United States;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 03:13:37

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号